Summary
This review article examines the current landscape of tumour biomarkers and their utility in clinical oncology. The authors likely synthesise evidence on molecular, genetic and protein-based biomarkers used to diagnose cancers, predict patient outcomes and guide precision medicine approaches. The work appears positioned as a comprehensive overview of biomarker discovery, validation and implementation in cancer care.
UK applicability
Findings are applicable to UK cancer diagnostics and NHS treatment pathways, where biomarker-driven precision oncology is increasingly integrated into standard care. However, implementation depends on diagnostic infrastructure, NHS capacity and health economic decisions.
Key measures
Biomarker sensitivity, specificity, prognostic value, predictive utility for treatment selection
Outcomes reported
The study reviewed the role of tumour biomarkers in cancer diagnosis, prognostication and selection of targeted therapeutic interventions. It synthesised evidence on biomarker classes and their clinical applications across cancer types.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.